286 related articles for article (PubMed ID: 29558274)
1. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Colombo N; Huang G; Scambia G; Chalas E; Pignata S; Fiorica J; Van Le L; Ghamande S; González-Santiago S; Bover I; Graña Suárez B; Green A; Huot-Marchand P; Bourhis Y; Karve S; Blakeley C
J Clin Oncol; 2018 May; 36(13):1300-1307. PubMed ID: 29558274
[TBL] [Abstract][Full Text] [Related]
2. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Rumford M; Lythgoe M; McNeish I; Gabra H; Tookman L; Rahman N; George A; Krell J
Sci Rep; 2020 Feb; 10(1):3390. PubMed ID: 32098980
[TBL] [Abstract][Full Text] [Related]
3. Oncologist-led
Yoon SY; Wong SW; Lim J; Ahmad S; Mariapun S; Padmanabhan H; Hassan NT; Lau SY; Ch'ng GS; Haniffa M; Ong WP; Rethanavelu K; Moey LH; Keng WT; Omar J; Mohd Abas MN; Yong CM; Ramasamy V; Md Noor MR; Aliyas I; Lim MCK; Suberamaniam A; Mat Adenan NA; Ahmad ZA; Ho GF; Abdul Malik R; Subramaniam S; Khoo BP; Raja A; Chin YS; Sim WW; Teh BH; Kho SK; Ong ESE; Voon PJ; Ismail G; Lee CL; Abdullah BZ; Loo KS; Lim CS; Lee SJ; Lim KJL; Shafiee MN; Ismail F; Latiff ZA; Ismail MP; Mohamed Jamli MF; Kumarasamy S; Leong KW; Low J; Md Yusof M; Ahmad Mustafa AM; Mat Ali NH; Makanjang M; Tayib S; Cheah N; Lim BK; Fong CK; Foo YC; Mellor Abdullah M; Tan TS; Chow DSY; Ho KF; Raman R; Radzi A; Deniel A; Teoh DCY; Ang SF; Joseph JK; Ng PHO; Tho LM; Ahmad AR; Muin I; Bleiker E; George A; Thong MK; Woo YL; Teo SH
J Med Genet; 2022 Mar; 59(3):220-229. PubMed ID: 33526602
[TBL] [Abstract][Full Text] [Related]
4.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.
Weiderpass E; Tyczynski JE
Mol Diagn Ther; 2015 Dec; 19(6):351-64. PubMed ID: 26476542
[TBL] [Abstract][Full Text] [Related]
6. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
7. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
[TBL] [Abstract][Full Text] [Related]
9. Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.
Agha N; Alshamsan B; Al-Farsi S; Ateya HA; Almugbel FA; Alotaibi HA; Omar A; Mohamed AS; Alharthy H; Elhassan T; Salem H; Alhusaini H
BMC Cancer; 2022 Jan; 22(1):18. PubMed ID: 34980015
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
Sun P; Li Y; Chao X; Li J; Luo R; Li M; He J
BMC Cancer; 2020 Oct; 20(1):994. PubMed ID: 33054725
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
12. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA
Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051
[TBL] [Abstract][Full Text] [Related]
13. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
14. Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Hodgson DR; Brown JS; Dearden SP; Lai Z; Elks CE; Milenkova T; Dougherty BA; Lanchbury JS; Perry M; Timms KM; Harrington EA; Barrett JC; Leary A; Pujade-Lauraine E
Gynecol Oncol; 2021 Dec; 163(3):563-568. PubMed ID: 34742578
[TBL] [Abstract][Full Text] [Related]
15. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
16. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
17. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
18. BRCA testing and outcomes in women with breast cancer.
Stenehjem DD; Telford C; Unni SK; Bauer H; Sainski A; Deka R; Schauerhamer MB; Ye X; Tak CR; Ma J; Dalvi TB; Gutierrez L; Kaye JA; Tyczynski JE; Brixner DI; Biskupiak JE
Breast Cancer Res Treat; 2021 Apr; 186(3):839-850. PubMed ID: 33389410
[TBL] [Abstract][Full Text] [Related]
19. Physicians' experiences with BRCA1/2 testing in community settings.
Keating NL; Stoeckert KA; Regan MM; DiGianni L; Garber JE
J Clin Oncol; 2008 Dec; 26(35):5789-96. PubMed ID: 19001322
[TBL] [Abstract][Full Text] [Related]
20. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR; Dougherty BA; Lai Z; Fielding A; Grinsted L; Spencer S; O'Connor MJ; Ho TW; Robertson JD; Lanchbury JS; Timms KM; Gutin A; Orr M; Jones H; Gilks B; Womack C; Gourley C; Ledermann J; Barrett JC
Br J Cancer; 2018 Nov; 119(11):1401-1409. PubMed ID: 30353044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
